Alvotech is trading 3.45% higher at ISK 720.00, with no clear catalyst for the move. - Latest company news includes a manufacturing agreement with LOTTE Biologics announced October 6 and FDA approval for additional SIMLANDI manufacturing capacity on October 5; neither establishes a direct cause for this session’s gain. - Market context is mixed, with no verified evidence tying broader market or biotech-sector activity to Alvotech’s rise.